TDMS Study 93021-06 Pathology Tables
NTP Experiment-Test: 93021-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: SUBCHRON 26-WEEK DICYCLOHEXYLCARBODIIMIDE (DCC) Date: 01/10/01
Route: SKIN APPLICATION Time: 09:20:54
Final #1/Mice
Facility: BIORELIANCE
Chemical CAS #: 538-75-0
Lock Date: 02/24/00
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 93021-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: SUBCHRON 26-WEEK DICYCLOHEXYLCARBODIIMIDE (DCC) Date: 01/10/01
Route: SKIN APPLICATION Time: 09:20:54
____________________________________________________________________________________________________________________________________
MICE:P53+/-(C57BL/6) FEMALE VEHICLE 0.75 1.5 3.0 6.0 12.0
MG/KG MG/KG MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 15 15 15 15 15 15
Early Deaths
Moribund Sacrifice 2 7
Natural Death 1 1 1
Survivors
Terminal Sacrifice 15 15 15 12 14 7
Animals Examined Microscopically 15 15 15 15 15 15
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Liver (15) (15) (15) (15) (14) (15)
Hematopoietic Cell Proliferation 1 (7%)
Hematopoietic Cell Proliferation, Focal 1 (7%)
Infiltration Cellular, Focal, Lymphocyte 1 (7%) 4 (27%) 1 (7%) 2 (13%)
Inflammation, Chronic Active, Focal 1 (7%)
Hepatocyte, Necrosis, Focal 4 (27%) 6 (40%) 5 (33%) 4 (27%) 2 (14%) 1 (7%)
Periportal, Vacuolization Cytoplasmic, Focal 1 (7%)
Stomach, Glandular (15) (15) (15) (15) (14) (14)
Infiltration Cellular, Focal, Lymphocyte 1 (7%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
None
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (15) (15) (15) (15) (14) (13)
Subcapsular, Hyperplasia 1 (8%)
Subcapsular, Hyperplasia, Focal 13 (87%) 13 (87%) 12 (80%) 13 (87%) 14 (100%) 9 (69%)
Thyroid Gland (13) (15) (15) (14) (13) (13)
Ectopic Thymus 2 (13%) 3 (20%) 1 (7%) 1 (8%)
Inflammation, Chronic Active, Focal 1 (8%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 2
NTP Experiment-Test: 93021-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: SUBCHRON 26-WEEK DICYCLOHEXYLCARBODIIMIDE (DCC) Date: 01/10/01
Route: SKIN APPLICATION Time: 09:20:54
____________________________________________________________________________________________________________________________________
MICE:P53+/-(C57BL/6) FEMALE VEHICLE 0.75 1.5 3.0 6.0 12.0
MG/KG MG/KG MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (15) (15) (15) (15) (14) (14)
Atrophy 1 (7%) 1 (7%)
Uterus (15) (15) (15) (15) (14) (14)
Endometrium, Hyperplasia, Cystic 14 (93%) 15 (100%) 15 (100%) 13 (87%) 13 (93%) 7 (50%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (15) (15) (15) (15) (14) (15)
Myeloid Cell, Hyperplasia 3 (20%) 1 (7%) 8 (53%)
Lymph Node (1)
Inguinal, Hyperplasia, Lymphoid 1 (100%)
Lymph Node, Mandibular (15) (15) (14) (14) (14) (14)
Hyperplasia, Lymphoid 1 (7%) 2 (14%) 3 (21%)
Lymph Node, Mediastinal (14) (15) (15) (12) (13) (13)
Hyperplasia, Lymphoid 1 (7%)
Spleen (15) (15) (15) (15) (14) (14)
Hematopoietic Cell Proliferation 15 (100%) 15 (100%) 15 (100%) 15 (100%) 13 (93%) 13 (93%)
Pigmentation 1 (7%)
Thymus (15) (15) (15) (15) (14) (13)
Atrophy, Diffuse 2 (15%)
Atrophy, Focal 2 (13%) 1 (7%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (15) (15) (15) (15) (14) (14)
Inflammation, Chronic Active, Focal 1 (7%)
Skin (15) (15) (15) (15) (15) (15)
Control, Ulcer, Focal 1 (7%) 2 (13%)
Dermis, Epidermis, Hyperplasia, Focal 1 (7%)
Dermis, Control, Inflammation, Chronic
Active, Focal 3 (20%) 1 (7%) 2 (13%)
Dermis, Skin, Site of Application, Fibrosis 1 (7%)
Dermis, Skin, Site of Application,
Inflammation, Chronic Active, Focal 1 (7%) 13 (87%) 2 (13%) 9 (60%)
Epidermis, Control, Hyperplasia, Focal 2 (13%) 1 (7%)
Epidermis, Skin, Site of Application,
Hyperplasia, Diffuse 1 (7%) 2 (13%)
Epidermis, Skin, Site of Application,
Hyperplasia, Focal 1 (7%) 5 (33%) 11 (73%) 1 (7%) 8 (53%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 3
NTP Experiment-Test: 93021-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: SUBCHRON 26-WEEK DICYCLOHEXYLCARBODIIMIDE (DCC) Date: 01/10/01
Route: SKIN APPLICATION Time: 09:20:54
____________________________________________________________________________________________________________________________________
MICE:P53+/-(C57BL/6) FEMALE VEHICLE 0.75 1.5 3.0 6.0 12.0
MG/KG MG/KG MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - CONT
Sebaceous Gland, Control, Hyperplasia, Focal 1 (7%) 1 (7%)
Sebaceous Gland, Skin, Site of Application,
Hyperplasia, Focal 3 (20%) 3 (20%)
Skin, Site of Application, Hyperkeratosis,
Diffuse 1 (7%) 1 (7%)
Skin, Site of Application, Parakeratosis,
Focal 1 (7%) 1 (7%)
Skin, Site of Application, Ulcer, Focal 2 (13%) 1 (7%) 8 (53%)
Subcutaneous Tissue, Control, Inflammation,
Chronic Active, Focal 1 (7%) 2 (13%)
Subcutaneous Tissue, Skin, Site of
Application, Inflammation, Chronic, Focal 1 (7%)
Subcutaneous Tissue, Skin, Site of
Application, Inflammation, Chronic
Active, Focal 2 (13%) 8 (53%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (15) (15) (15) (15) (14) (15)
Alveolar Epithelium, Hyperplasia, Focal 1 (7%)
Alveolar Epithelium, Inflammation, Chronic
Active, Focal 1 (7%)
Alveolus, Inflammation, Chronic Active, Focal 1 (7%) 1 (7%) 1 (7%)
Perivascular, Infiltration Cellular, Focal,
Lymphocyte 1 (7%) 2 (14%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
None
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 4
NTP Experiment-Test: 93021-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: SUBCHRON 26-WEEK DICYCLOHEXYLCARBODIIMIDE (DCC) Date: 01/10/01
Route: SKIN APPLICATION Time: 09:20:54
____________________________________________________________________________________________________________________________________
MICE:P53+/-(C57BL/6) FEMALE VEHICLE 0.75 1.5 3.0 6.0 12.0
MG/KG MG/KG MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (15) (15) (15) (15) (14) (14)
Infiltration Cellular, Focal, Lymphocyte 1 (7%)
Pelvis, Infiltration Cellular, Focal,
Lymphocyte 1 (7%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 5
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------